Literature DB >> 17372913

Gains and complex rearrangements of the 12q13-15 chromosomal region in ordinary lipomas: the "missing link" between lipomas and liposarcomas?

Antoine Italiano1, Nathalie Cardot, Florence Dupré, Isabelle Monticelli, Frédérique Keslair, Marjorie Piche, Claire Mainguené, Jean-Michel Coindre, Florence Pedeutour.   

Abstract

Well-differentiated liposarcomas (WDLPS) classically contain high-level amplification of 12q14-15 sequences, including the MDM2 and CDK4 genes, while lipomas are characterized by simple structural chromosome aberrations often involving HMGA2 at 12q15. Previous studies have shown that low-level gain of the 12q14-15 region, such as trisomy 12 and 12q15-24 duplication, might be sufficient for the development of minimal atypia and formation of WDLPS. Moreover, because some features, such as overexpression of HMGA2, are shared by both lipomas and WDLPS, it has been hypothesized that lipomas and WDLPS may form a genetic and morphological continuum. We report here the results of molecular cytogenetic analysis of 8 lipomas that had unusual chromosomal features resulting in gains of 12q14-15. While 3 cases had simple numerical rearrangements (trisomy 12) or structural rearrangements (unbalanced translocations with 12q gains), 5 cases were particularly intriguing because of peculiar features such as giant chromosomes, supernumerary chromosomes or neocentromeres that usually are the hallmark of WDLPS. Gain of 12q14-15 sequences including extra copies of MDM2 and CDK4 were detected by fluorescence in situ hybridization analysis in all analyzed cases but no expression of MDM2 and CDK4 was observed suggesting that these genomic imbalances had no functional consequence. We observed rearrangements of HMGA2 in 5 out 8 cases. Altogether, our results indicate that moderate gains of 12q are not always associated with a malignant phenotype, and that some intermediary forms exist between classical lipomas and classical WDLPS. Some of these intermediary forms may correspond to a genomic premalignant condition while some may have no malignant potential. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17372913     DOI: 10.1002/ijc.22685

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience.

Authors:  Ronald S A de Vreeze; Daphne de Jong; Petra M Nederlof; Aafke Ariaens; Ivon H G Tielen; Luc Frenken; Rick L Haas; Frits van Coevorden
Journal:  Ann Surg Oncol       Date:  2010-03       Impact factor: 5.344

2.  Giant lipoma of the thenar--case study and contemporary approach to its aetiopathogenicity.

Authors:  T B Grivas; S A Psarakis; Alpha Kaspiris; G Liapi
Journal:  Hand (N Y)       Date:  2008-12-18

Review 3.  HMGA2 and high-grade serous ovarian carcinoma.

Authors:  Jingjing Wu; Jian-Jun Wei
Journal:  J Mol Med (Berl)       Date:  2013-05-19       Impact factor: 4.599

4.  [Lipoma and atypical lipomatous tumor within the same neoplasia: Evidence for a continuous transition].

Authors:  C Kuhnen; T Mentzel; M Lehnhardt; H H Homann; R Sciot; M Debiec-Rychter
Journal:  Pathologe       Date:  2010-03       Impact factor: 1.011

5.  Malignant fibrous histiocytoma--pleomorphic sarcoma, NOS gene expression, histology, and clinical course. A pilot study.

Authors:  Adrien Daigeler; Daigeler Adrien; Ludger Klein-Hitpass; Klein-Hitpass Ludger; Ingo Stricker; Stricker Ingo; Oliver Müller; Müller Oliver; Cornelius Kuhnen; Kuhnen Cornelius; Ansgar Michael Chromik; Chromik Ansgar Michael; Lars Steinstraesser; Steinstraesser Lars; Ole Goertz; Goertz Ole; Hans-Ulrich Steinau; Steinau Hans-Ulrich; Marcus Lehnhardt; Lehnhardt Marcus
Journal:  Langenbecks Arch Surg       Date:  2009-01-22       Impact factor: 3.445

6.  Duplication of chromosome segment 12q13-15 in a lipomatous tumor with minimal nuclear atypia: A case report.

Authors:  Jun Nishio; Hiroshi Iwasaki; Terufumi Shibata; Kazuki Nabeshima; Masatoshi Naito
Journal:  Oncol Lett       Date:  2016-03-07       Impact factor: 2.967

7.  HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status.

Authors:  Wen-Bin Ou; Jiaqing Zhu; Grant Eilers; Xuhui Li; Ye Kuang; Li Liu; Adrián Mariño-Enríquez; Ziqin Yan; Hailong Li; Fanguo Meng; Haimeng Zhou; Qing Sheng; Jonathan A Fletcher
Journal:  Oncotarget       Date:  2015-04-30

8.  Expression levels of HMGA2 in adipocytic tumors correlate with morphologic and cytogenetic subgroups.

Authors:  Hammurabi Bartuma; Ioannis Panagopoulos; Anna Collin; Domenico Trombetta; Henryk A Domanski; Nils Mandahl; Fredrik Mertens
Journal:  Mol Cancer       Date:  2009-06-09       Impact factor: 27.401

9.  Heterogeneous in vitro effects of doxorubicin on gene expression in primary human liposarcoma cultures.

Authors:  Adrien Daigeler; Ludger Klein-Hitpass; Michael Ansgar Chromik; Oliver Müller; Jörg Hauser; Heinz-Herbert Homann; Hans-Ulrich Steinau; Marcus Lehnhardt
Journal:  BMC Cancer       Date:  2008-10-29       Impact factor: 4.430

10.  12q14 microduplication: a new clinical entity reciprocal to the microdeletion syndrome?

Authors:  Sofia Dória; Daniela Alves; Maria João Pinho; Joel Pinto; Miguel Leão
Journal:  BMC Med Genomics       Date:  2020-01-03       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.